Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician–Patient Real-World Clinical Data Analysis

Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A... Oncol Ther (2018) 6:73–85 https://doi.org/10.1007/s40487-018-0059-5 ORIGINAL RESEARCH Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician– Patient Real-World Clinical Data Analysis . . . . Tony Lough Qingyang Luo Paul O’Sullivan Christophe Chemasle ´ . . Michael Stotzer James Suttie David Darling Received: February 15, 2018 / Published online: April 19, 2018 The Author(s) 2018 physicians who each evaluated the same real- ABSTRACT world clinical case data for 30 patients under- going surveillance for recurrent UC. Each Introduction: International guidelines advo- physician ordered tests and procedures and cate regular surveillance of patients following their timing, following review of the patient’s urothelial carcinoma (UC). A validated molec- demographic data, pre-existing conditions, risk ular diagnostic non-invasive urine test, factors and clinical history before and after Cxbladder Monitor, correctly identifies patients disclosure of Cxbladder Monitor results. Chan- with a UC history who have low-probability of ges in the number, type and timing of proce- recurrence. The present study assesses the clin- dures ordered were assessed. ical utility of Cxbladder Monitor in reducing Results: The addition of Cxbladder Monitor the number and frequency of urologic proce- significantly reduced the overall number of tests dures ordered without missing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician–Patient Real-World Clinical Data Analysis

Download PDF
13 pages

Loading next page...
 
/lp/springer-journals/clinical-utility-of-cxbladder-monitor-for-patients-with-a-history-of-uar2UH6yWG
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0059-5
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2018) 6:73–85 https://doi.org/10.1007/s40487-018-0059-5 ORIGINAL RESEARCH Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician– Patient Real-World Clinical Data Analysis . . . . Tony Lough Qingyang Luo Paul O’Sullivan Christophe Chemasle ´ . . Michael Stotzer James Suttie David Darling Received: February 15, 2018 / Published online: April 19, 2018 The Author(s) 2018 physicians who each evaluated the same real- ABSTRACT world clinical case data for 30 patients under- going surveillance for recurrent UC. Each Introduction: International guidelines advo- physician ordered tests and procedures and cate regular surveillance of patients following their timing, following review of the patient’s urothelial carcinoma (UC). A validated molec- demographic data, pre-existing conditions, risk ular diagnostic non-invasive urine test, factors and clinical history before and after Cxbladder Monitor, correctly identifies patients disclosure of Cxbladder Monitor results. Chan- with a UC history who have low-probability of ges in the number, type and timing of proce- recurrence. The present study assesses the clin- dures ordered were assessed. ical utility of Cxbladder Monitor in reducing Results: The addition of Cxbladder Monitor the number and frequency of urologic proce- significantly reduced the overall number of tests dures ordered without missing

Journal

Oncology and Therapy – Springer Journals

Published: Apr 19, 2018

References

  • Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study
  • Surveillance and treatment of non-muscle-invasive bladder cancer in the USA
    Barocas, DA; Globe, DR; Colayco, DC; Onyenwenyi, A; Bruno, AS; Bramley, TJ
  • Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis
    Ahmad, I; Patel, R; Liu, Y; Singh, LB; Taketo, MM; Wu, X-R
  • Recurrence of high-risk bladder cancer: a population-based analysis
    Chamie, K; Litwin, MS; Bassett, JC; Daskivich, TJ; Lai, J; Hanley, JM
  • Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
    Sylvester, RJ; Meijden, APM; Oosterlinck, W; Witjes, JA; Bouffioux, C; Denis, L
  • Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline
    Chang, SS; Boorjian, SA; Chou, R; Clark, PE; Daneshmand, S; Konety, BR
  • Bladder cancer
    Clark, PE; Agarwal, N; Biagioli, MC; Eisenberger, MA; Greenberg, RE; Herr, HW
  • EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016
    Babjuk, M; Böhle, A; Burger, M; Capoun, O; Cohen, D; Compéat, EM
  • The health economics of bladder cancer: an updated review of the published literature
    Yeung, C; Dinh, T; Lee, J
  • What is the clinical utility of genetic testing?
    Grosse, SD; Khoury, MJ
  • Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer
    Parkinson, DR; McCormack, RT; Keating, SM; Gutman, SI; Hamilton, SR; Mansfield, EA
  • New thinking on clinical utility: hard lessons for molecular diagnostics
    Peabody, JW; Shimkhada, R; Tong, KB; Zubiller, MB
  • Economic aspects of bladder cancer: what are the benefits and costs?
    Sievert, KD; Amend, B; Nagele, U; Schilling, D; Bedke, J; Horstmann, M
  • Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma
    Lotan, Y; O’Sullivan, P; Raman, JD; Shariat, SF; Kavalieris, L; Frampton, C
  • Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer
    Mowatt, G; Zhu, S; Kilonzo, M; Boachie, C; Fraser, C; Griffiths, TRL
  • Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses
    Lotan, Y; Roehrborn, CG
  • Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
    Bekker-Grob, EW; Aa, MNM; Zwarthoff, EC; Eijkemans, MJC; Rhijn, BW; Kwast, TH
  • The burden of cystoscopic bladder cancer surveillance: anxiety, discomfort, and patient preferences for decision making
    Koo, K; Zubkoff, L; Sirovich, BE; Goodney, PP; Robertson, DJ; Seigne, JD
  • Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study
    Kavalieris, L; O’Sullivan, P; Frampton, C; Guilford, P; Darling, D; Jacobson, E
  • Clinical utility of Cxbladder for the diagnosis of urothelial carcinoma
    Darling, D; Luxmanan, C; O’Sullivan, P; Lough, T; Suttie, J
  • Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis
    Lough, T; Luo, Q; Luxmanan, C; Anderson, A; Suttie, J; O’Sullivan, P; Darling, D